J Int Med Res 2016 Sep;44(1 suppl):72-75
Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.
Aim: To investigate the role of body mass index (BMI) and weight in the long-term efficacy of etanercept in patients with psoriasis.
Methods: Medical records were retrospectively analysed. Extracted data included weight, BMI, comorbidities and psoriasis area severity index (PASI). Patients were stratified by weight (<80 kg or ≥80 kg) and BMI (healthy, BMI 22 - 24.99 kg/m; overweight, BMI 25 - 29.99 kg/m; obese, BMI ≥30 kg/m).
Results: The study included 66 patients. Body weight had no effect on etanercept efficacy. There was a significant reduction in etanercept efficacy in obese patients (n = 12) compared with healthy weight (n = 33) or overweight (n = 21) patients.
Conclusion: Obesity has a negative effect on the efficacy of etanercept in psoriasis.